石药创新 (300765.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−189.1x

Market Cap

CNY 63.54B

MomentumView details →

1D Return

−7.67%

YTD Return

+21.65%

RSI (14)

52.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−189.1x

Market Cap

CNY 63.54B

RSI (14)

52.7

MomentumView details →

1D Return

−7.67%

YTD Return

+21.65%

ProfitabilityView details →

Gross Margin

38.84%

Net Margin

−13.11%

EBITDA Margin

−13.75%

ROE (TTM)

−11.95%

ROA (TTM)

−4.96%

Asset Turnover

0.38x

GrowthView details →

Revenue YoY

+21.87%

EPS YoY

—

FCF YoY

−0.36%

Revenue CAGR 3Y

−6.34%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.97

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

−0.94%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

1.00x

Quick Ratio

0.83x

Div Yield

—

Div Rate

—

Div Growth 1Y

−93.75%

Financials snapshotView financials →

Revenue (TTM)

2.35B

Net Income (TTM)

−308.08M

Op. CF (TTM)

−288.41M

Next earningsOct 28, 2026 →

Latest newsMore news →

Shijiazhuang Pharma Innovation's controlled subsidiary Shijiazhuang Pharmaceutical Group Jushi Biopharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its SYH2092 injection in China.8d ago

As of August 20, 2026, the total margin trading balance on China's A-share market decreased by 1.248 billion yuan to 2.666356 trillion yuan, with net financing purchases led by Zhongji Innolight at 530 million yuan.15d ago

Similar companies

国瓷材料300285.SZ 君正股份300223.SZ 云南锗业002428.SZ 中国稀土000831.SZ 科伦药业002422.SZ 中联重科000157.SZ Find similar companies →

Latest newsMore news →

Shijiazhuang Pharma Innovation's controlled subsidiary Shijiazhuang Pharmaceutical Group Jushi Biopharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its SYH2092 injection in China.8d ago As of August 20, 2026, the total margin trading balance on China's A-share market decreased by 1.248 billion yuan to 2.666356 trillion yuan, with net financing purchases led by Zhongji Innolight at 530 million yuan.15d ago